Research Analysts Set Expectations for CLDX FY2028 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Equities research analysts at Leerink Partnrs dropped their FY2028 earnings per share (EPS) estimates for Celldex Therapeutics in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will earn $1.04 per share for the year, down from their previous estimate of $1.24. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.50) per share.

Other research analysts have also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday. The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. Finally, Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX opened at $26.22 on Friday. Celldex Therapeutics has a fifty-two week low of $24.43 and a fifty-two week high of $53.18. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -10.20 and a beta of 1.60. The business’s 50 day moving average price is $33.60 and its 200-day moving average price is $35.82.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 20.41% and a negative net margin of 1,544.32%. The firm had revenue of $2.50 million for the quarter, compared to the consensus estimate of $1.13 million.

Institutional Trading of Celldex Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Arizona State Retirement System boosted its position in shares of Celldex Therapeutics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock worth $601,000 after purchasing an additional 325 shares in the last quarter. KBC Group NV boosted its position in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 638 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its position in shares of Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 1,504 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.